SLP

AI MemoPost-earnings T+3

Simulations Plus

As of 2026-07-14/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Altaris acquisition remains the dominant price anchor • 2026-10-12

Base target: $18 / p=15% prob

Biggest risk

Software revenue was flat in Q3 and down 2% year to date, adjusted EPS declined, and the expected closing remains subject to approvals. The stock is already close to the cash offer, leaving little upside and meaningful downside if the transaction breaks.

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The $18.50 cash consideration provides a near-term valuation anchor, while Q3 services growth and improved gross margin show resilience. Strategic AI and platform opportunities may support execution until closing.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-14

Base target

$18

p=15%

Bull target

$19

p=75%

Bear target

$16

p=10%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Mixed Q3 FY2026 print limits operating rerating
Services and AI-enabled platform execution through the transition
The $18.50 cash consideration provides a near-term valuation anchor, while Q3 services growth and improved gross margin show resilience.

BearKey bullets

Adjusted diluted EPS fell year over year and acquisition-related costs, taxes, and other non-GAAP adjustments reduce forward earnings visibility.
Altaris transaction failure, delay, or adverse shareholder or regulatory outcome could cause a material repricing toward standalone value.
Low analyst coverage and loose peers limit external validation of standalone valuation.

WatchKey bullets

Altaris acquisition remains the dominant price anchor

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $18 (p=15%)

Target spread vs base: +1% / -15%

Scenario probabilities

Bull Target: $19 (p=75%)Base Target: $18 (p=15%)Bear Target: $16 (p=10%)

Commentary

The official Q3 release was operationally mixed but strategically supported by the announced acquisition. Secondary coverage reported only a modest post-print price response, while post-earnings analyst revision evidence remains limited. With the stock near the $18.50 cash offer, sentiment is best viewed as cautious, event-driven monitoring rather than broadly bullish. [MarketBeat post-print coverage](https://www.marketbeat.com/instant-alerts/simulations-plus-nasdaqslp-releases-fy-2026-earnings-guidance-2026-07-10/)

As of 2026-07-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Mixed Q3 FY2026 print limits operating rerating
Services and AI-enabled platform execution through the transition

Scenarios

Bull Target (Scenario probability)

$19 / p=75% prob

Base Target (Scenario probability)

$18 / p=15% prob

Bear Target (Scenario probability)

$16 / p=10% prob

Analysis 2026-07-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-12
Altaris acquisition remains the dominant price anchor
Simulations Plus agreed to an all-cash acquisition at $18.50 per share, with closing currently expected in calendar Q4 2026 and subject to shareholder, regulatory, and other customary conditions. The official release states there is no financing contingency. [Simulations Plus merger release](https://www.simulations-plus.com/resource/simulations-plus-to-be-acquired-by-altaris-for-approximately-375-million/)
Prob 75.00% • Move 1.40% • Priced-in 95.00%

Short-term Catalysts

Next few weeks

Mixed Q3 FY2026 print limits operating rerating
2026-07-09
Q3 revenue rose 7% to $21.9 million and services revenue rose 20%, but software revenue was flat; adjusted diluted EPS declined to $0.30 from $0.45. The Q3 filing deck also flags renewal pressure from client consolidations and site closures. [#SEC-8K-2026-07-09]
Prob 90% • Move -3% • Priced-in 85%

Long-term Catalysts

Months to a year

Services and AI-enabled platform execution through the transition
2026-09-30
Services growth, continued client adoption, and AI-enabled workflow development could support results through the expected transaction close, but software weakness, limited coverage, and the $18.50 consideration cap the public-equity upside. [#8-K-2026-07-09](https://www.simulations-plus.com/resource/simulations-plus-reports-third-quarter-fiscal-2026-financial-results/)
Prob 45% • Move 2% • Priced-in 80%

Risks

Adjusted diluted EPS fell year over year and acquisition-related costs, taxes, and other non-GAAP adjustments reduce forward earnings visibility.
Altaris transaction failure, delay, or adverse shareholder or regulatory outcome could cause a material repricing toward standalone value.
Low analyst coverage and loose peers limit external validation of standalone valuation.
Software renewals remain exposed to client consolidations and site closures, while nine-month software revenue declined 2%.

Peers

Symbol	Summary
AUNA	Small-cap health care services proxy with similar market-cap scale, but business and regulatory drivers are not directly comparable to drug-development software and services.
CARL	Small-cap medical-device proxy; useful only for sector risk appetite, with limited operating read-through to SLP.
ELMD	Small-cap medical-device company and loose sector-cap proxy; business model differences make relative valuation inconclusive.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-14

Loading AI feed…

Symbol

Summary

AUNA

Small-cap health care services proxy with similar market-cap scale, but business and regulatory drivers are not directly comparable to drug-development software and services.

CARL

Small-cap medical-device proxy; useful only for sector risk appetite, with limited operating read-through to SLP.

ELMD

Small-cap medical-device company and loose sector-cap proxy; business model differences make relative valuation inconclusive.